Latest news with #Mounjaro®
Cision Canada
13-05-2025
- Health
- Cision Canada
LILLY CANADA ANNOUNCES AVAILABILITY OF MOUNJARO® KWIKPEN® (TIRZEPATIDE INJECTION) IN ALL DOSES, ADVANCING CARE FOR ADULTS LIVING WITH TYPE 2 DIABETES Français
The multi-dose, single-patient-use, prefilled pen allows for personalized treatment plans that can cater to individual patient needs , May 13, 2025 /CNW/ - Lilly Canada is pleased to announce that Mounjaro ® KwikPen ® (tirzepatide injection) is now available in Canada in all doses, offering a convenient treatment option for adults with type 2 diabetes. Mounjaro ® is the first and only Health Canada-authorized once-weekly glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist and is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. 1 Mounjaro ® KwikPen ® is a multi-dose single-patient-use prefilled pen. Each Mounjaro ® KwikPen ® contains four fixed doses of 0.6 mL, each dose taken once weekly. 2 It is available in six different dose strengths (2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg), 3 providing healthcare providers with the ability to personalize treatment plans to better meet individual patient needs. "The availability of all doses of Mounjaro KwikPen represents a significant step forward for people living with type 2 diabetes," says Dr. Akshay Jain, Clinical and Research Endocrinologist in Surrey, BC. "The KwikPen may help support greater convenience when traveling and may help reduce the risk of dosing errors, making type 2 diabetes management less burdensome for patients." Over 5 million adults are living with diabetes in Canada, of which 90 per cent of the cases are type 2 diabetes. 4 If left unmanaged, this chronic disease can lead to heart attacks, strokes, kidney failure, and blindness, and could reduce lifespan by five to 15 years. 5 The launch of Mounjaro ® KwikPen ® represents a step forward in type 2 diabetes care, offering a convenient way for patients to administer their medication. "Lilly Canada is dedicated to providing innovative medicines that create positive impacts in the lives of Canadians and help reduce the burden on our healthcare system," says Kenneth Custer, Lilly Canada President and General Manager. "Mounjaro represents an important advancement for people with type 2 diabetes and Mounjaro KwikPen will allow us to meet the future demand for this medicine in Canada." Mounjaro ® KwikPen ® is now available by prescription across Canada. Patients should consult with their healthcare provider to determine if Mounjaro ® KwikPen ® is the right treatment option for them. About Mounjaro ® (tirzepatide) injection 5 Mounjaro ® (tirzepatide) is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. As the first and only Health Canada-approved GIP and GLP-1 receptor agonist, Mounjaro is a single molecule that activates the body's receptors for GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1). To view the full Mounjaro ® product monograph, please visit Lilly is committed to helping people access the medicines they are prescribed, and will work with insurers, health systems and providers to help enable patient access to Mounjaro. Lilly offers a Patient Support Program for eligible patients. Patients or healthcare professionals with questions about Mounjaro can visit or call the Lilly Customer Response Centre at 1-888-545-5972. About Lilly Canada Eli Lilly and Company is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by Colonel Eli Lilly, who was committed to creating high quality medicines that meet people's needs, and today we remain true to that mission in all our work. Lilly employees work to discover and bring life-changing medicines to people who need them, improve the understanding and management of disease, and contribute to our communities through philanthropy and volunteerism. Eli Lilly Canada was established in 1938, the result of a research collaboration with scientists at the University of Toronto which eventually produced the world's first commercially available insulin. Our work focuses on oncology, diabetes, autoimmunity, neurodegeneration, and pain. To learn more about Lilly Canada, please visit us at SOURCE Eli Lilly Canada Inc.
India Gazette
12-05-2025
- Health
- India Gazette
Weight loss drug Mounjaro shown more effective than Wegovy, claims Pharma company
New Delhi [India], May 12 (ANI): Eli Lilly and Company announced on Monday detailed results from SURMOUNT-5, a phase 3b open-label clinical trial, evaluating the safety and efficacy of tirzepatide, a dual GIP and GLP-1 receptor agonist, compared to semaglutide, a mono GLP-1 receptor agonist, in adults living with obesity, or overweight with at least one weight-related medical problem and without diabetes, according to a press statement. According to Eli Lilly, participants reduced 20.2 per cent weight with tirzepatide in comparison to 13.7 per cent with semaglutide across the trials. At 72 weeks, tirzepatide met the primary endpoint and all five key secondary endpoints, demonstrating superiority compared to semaglutide across the trial. The detailed results were presented at the 32nd European Congress on Obesity (ECO) and simultaneously published in The New England Journal of Medicine. The statement added, 'For the primary endpoint, participants treated with tirzepatide achieved an average weight reduction of 20.2 per cent compared to 13.7 per cent with semaglutide at 72 weeks using treatment-regimen estimand,1 47 per cent greater relative weight loss. Participants using tirzepatide lost an average of 22.8 kg and participants on semaglutide lost an average of 15.0 kg.2.' In key secondary endpoints, tirzepatide was superior across all weight reduction targets with 64.6 per cent of participants treated with tirzepatide achieving at least 15.0 per cent weight loss compared to 40.1 per cent on semaglutide. Additionally, participants treated with tirzepatide achieved a superior average waist circumference reduction of 7.2 in (18.4 cm), while those treated with semaglutide saw an average reduction of 5.1 in (13.0 cm). 'Thanks to the latest advancements in obesity management medications, more physicians and patients are witnessing significant weight reduction beyond what they have seen before,' said Louis J. Aronne, MD, FACP, DABOM, director of the Comprehensive Weight Control Center and the Sanford I. Weill Professor of Metabolic Research at Weill Cornell Medicine, obesity expert at New York-Presbyterian/Weill Cornell Medical Center, and investigator of SURMOUNT-5,' as per the statement. 'The SURMOUNT-5 head-to-head results demonstrated that tirzepatide led to greater weight reduction compared to semaglutide, providing further evidence to support tirzepatide as an effective option for obesity management.' 'Obesity is a chronic disease that requires comprehensive management, and Lilly is committed to supporting people with obesity and enhancing the standard of care in obesity management in India', said Winselow Tucker, President and General Manager, Eli Lilly and Company (India). 'The results from the SURMOUNT 5 trial provide robust evidence supporting Mounjaro (tirzepatide) as an effective option for obesity management in India.' The safety profile of tirzepatide in SURMOUNT-5 was consistent with previous SURMOUNT trials. Adverse events reported during the trial were primarily gastrointestinal-related and were generally mild to moderate in severity. During the trial, 6.1 per cent of participants taking tirzepatide discontinued treatment due to adverse events, compared to eight per cent of participants taking semaglutide. However, the study was not powered to compare the safety and tolerability of tirzepatide and the safety and tolerability of semaglutide. Tirzepatide is a weight loss drug for adults with obesity or with overweight who also have weight-related medical problems, as Zepbound in the US and Mounjaro in some countries outside of the US Tirzepatide is also commercialised as Mounjaro for adults with type 2 diabetes in the US and in some countries outside of the US. Semaglutide is a drug used as Wegovy for people living with obesity or for overweight adults who also have weight-related medical problems and Ozempic for people with type 2 diabetes. (ANI)
Associated Press
08-04-2025
- Business
- Associated Press
HealthJoy Partners With CareValidate to Transform GLP-1 Access and Affordability
Collaboration offers up to 50% savings on GLP-1 medications while protecting employer pharmacy spend CHICAGO, ILLINOIS / ACCESS Newswire / April 8, 2025 / HealthJoy, a leader in healthcare navigation, today announced a landmark partnership with CareValidate to enhance access and affordability of popular GLP-1 receptor agonists. This strategic collaboration delivers substantial discounts to members while safeguarding employer pharmacy spend. The partnership comes at a critical time as demand for GLP-1 medications like Ozempic®, Wegovy®, and Mounjaro® continues to surge. Weight loss medications are the most requested class of medications by HealthJoy members. With 2-3% of U.S. adults currently taking these medications and up to 20% expressing interest, employers face increasing pressure to provide access despite monthly retail costs of $900-$1,300. Through this collaboration, HealthJoy offers: 'What makes GLP-1s so compelling is their ability to address multiple drivers of cardiometabolic disease in a single therapy. This is why they have already become a foundational tool in how we approach metabolic health at scale,' said Jiten Chhabra, Chief Medical Officer at CareValidate. 'Now we can move upstream and tackle the root causes of cardiometabolic disease instead of just managing their complications, which has been the industry approach for far too long. This is truly a game-changer for population health and long-term cost savings for employers.' In addition to this partnership, HealthJoy is making technology enhancements to help employers control spend. By integrating with a leading pharmacy coupon service, HealthJoy identifies cost-saving opportunities - up to 80% off retail prices - and delivers personalized recommendations directly to members within the app. 'As pharmacy costs continue to dominate benefits discussions, employers need innovative solutions that balance access with affordability,' said Justin Holland, CEO and Co-Founder of HealthJoy. 'Our approach transforms how organizations can support employee health needs while strategically managing their pharmacy spend.' These innovations arrive as employers begin to plan their 2026 benefits strategy and seek solutions that improve medication access without complex plan redesigns. ABOUT HEALTHJOY HealthJoy is transforming the healthcare benefits experience by combining intuitive technology with human guidance to drive smarter care decisions. The company's proactive approach reduces claims costs, leading to a 21% decrease in healthcare spend and measurable savings for employers. With 80% of members following HealthJoy's care recommendations, organizations benefit from healthier teams, improved ROI, and more effective benefits strategies. Following its Series D funding, HealthJoy now serves over 1 million members and dependents across 1,800 employer clients. Backed by 14 strategic investors, the company remains committed to simplifying healthcare navigation and lowering costs. For more information, visit
